IL-15-话题@MedSci - 梅斯（MedSci）

#IL-15#

8篇内容 | 1118人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2240530, encodeId=5e41224053023, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a> <a href='/topic/show?id=8dcd12852f1' target=_blank style='color:#2F92EE;'>#NK细胞#</a>, objectTitle=Front Med：细胞内检查点有望用于开发基于NK细胞的癌症免疫疗法, objectType=article, longId=853699, objectId=0c3f85369981, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20241203/1733183291770_2185383.png, objectUrl=/article/show_article.do?id=0c3f85369981, replyNumber=0, likeNumber=9, createdTime=2024-12-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2003310, encodeId=27ce200331091, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, objectTitle=Nature Medicine：令人兴奋：IL-15超级激动剂治疗艾滋病的1期临床结果发布, objectType=article, longId=295116, objectId=8f862951163b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f862951163b, replyNumber=0, likeNumber=108, createdTime=2022-10-07, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f862951163b, moduleTitle=Nature Medicine：令人兴奋：IL-15超级激动剂治疗艾滋病的1期临床结果发布, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8f862951163b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2003309, encodeId=4ca5200330982, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, objectTitle=ASCO GU 2021: IL-15RαFc超激动剂N-803在对BCG反应的NMIBC膀胱癌原位癌患者中的研究（QUILT 3.032试验）, objectType=article, longId=207193, objectId=f13120e19316, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f13120e19316, replyNumber=0, likeNumber=120, createdTime=2022-01-01, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f13120e19316, moduleTitle=ASCO GU 2021: IL-15RαFc超激动剂N-803在对BCG反应的NMIBC膀胱癌原位癌患者中的研究（QUILT 3.032试验）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f13120e19316)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2003308, encodeId=c078200330835, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, objectTitle=哮喘治疗新突破：IL-15Rα单抗FASENRA让62%的患者摆脱口服糖皮质激素, objectType=article, longId=202761, objectId=152c202e61d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=152c202e61d8, replyNumber=0, likeNumber=80, createdTime=2020-11-24, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=152c202e61d8, moduleTitle=哮喘治疗新突破：IL-15Rα单抗FASENRA让62%的患者摆脱口服糖皮质激素, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=152c202e61d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2003307, encodeId=fb3a200330e21, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, objectTitle=AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用, objectType=article, longId=196499, objectId=fcb619649997, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcb619649997, replyNumber=0, likeNumber=82, createdTime=2021-05-16, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcb619649997, moduleTitle=AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fcb619649997)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2003306, encodeId=c8612003306ce, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, objectTitle=Calypso Biotech获得2000万欧元融资以开发IL-15单抗治疗自身免疫性疾病, objectType=article, longId=160663, objectId=367416066333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=367416066333, replyNumber=0, likeNumber=104, createdTime=2019-12-11, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=367416066333, moduleTitle=Calypso Biotech获得2000万欧元融资以开发IL-15单抗治疗自身免疫性疾病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=367416066333)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2003304, encodeId=11bf200330422, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, objectTitle=Blood：IL-15强兴奋剂复合物ALT-803用于干细胞移植后复发的恶性血液病的效果, objectType=article, longId=130269, objectId=e0641302692b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0641302692b, replyNumber=0, likeNumber=102, createdTime=2019-01-15, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0641302692b, moduleTitle=Blood：IL-15强兴奋剂复合物ALT-803用于干细胞移植后复发的恶性血液病的效果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e0641302692b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2003305, encodeId=db5f2003305a5, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, objectTitle=Lancet oncol：ALT-803（IL-15强激动剂）联合nivolumab用于转移性非小细胞肺癌安全性可耐受, objectType=article, longId=134404, objectId=edd7134404aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edd7134404aa, replyNumber=0, likeNumber=94, createdTime=2018-07-30, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edd7134404aa, moduleTitle=Lancet oncol：ALT-803（IL-15强激动剂）联合nivolumab用于转移性非小细胞肺癌安全性可耐受, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=edd7134404aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2003303, encodeId=3930200330316, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, objectTitle=Cancer Cell: IL-15可能是慢性炎症致癌的重要机制, objectType=article, longId=11102, objectId=1c1511102cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c1511102cd, replyNumber=0, likeNumber=0, createdTime=2013-03-30, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c1511102cd, moduleTitle=Cancer Cell: IL-15可能是慢性炎症致癌的重要机制, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1c1511102cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IL-15

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#IL-15# #NK细胞#

2024-12-03发表于上海

wetgdt (审核中...)

前往app查看评论内容

#IL-15#

Nature Medicine：令人兴奋：IL-15超级激动剂治疗艾滋病的1期临床结果发布

2022-10-07

wetgdt (审核中...)

前往app查看评论内容

#IL-15#

ASCO GU 2021: IL-15RαFc超激动剂N-803在对BCG反应的NMIBC膀胱癌原位癌患者中的研究（QUILT 3.032试验）

2022-01-01

wetgdt (审核中...)

前往app查看评论内容

#IL-15#

哮喘治疗新突破：IL-15Rα单抗FASENRA让62%的患者摆脱口服糖皮质激素

2020-11-24

wetgdt (审核中...)

前往app查看评论内容

#IL-15#

AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用

2021-05-16

wetgdt (审核中...)

前往app查看评论内容

#IL-15#

Calypso Biotech获得2000万欧元融资以开发IL-15单抗治疗自身免疫性疾病

2019-12-11

wetgdt (审核中...)

前往app查看评论内容

#IL-15#

Blood：IL-15强兴奋剂复合物ALT-803用于干细胞移植后复发的恶性血液病的效果

2019-01-15

wetgdt (审核中...)

前往app查看评论内容

#IL-15#

Lancet oncol：ALT-803（IL-15强激动剂）联合nivolumab用于转移性非小细胞肺癌安全性可耐受

2018-07-30

wetgdt (审核中...)

前往app查看评论内容

#IL-15#

Cancer Cell: IL-15可能是慢性炎症致癌的重要机制

2013-03-30

科室
- - 订阅+
  - 更多科室
工具
服务